within Pharmacolibrary.Drugs.ATC.A;

model A10BX02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.62,
    Cl             = 0.0006333333333333333,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02666666666666667,
    Tlag           = 600,            
    Vdp             = 0.062,
    k12             = 67,
    k21             = 67
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Repaglinide is an oral antihyperglycemic agent of the meglitinide class used to manage type 2 diabetes mellitus by stimulating insulin secretion from the pancreas. It is approved and widely used today for glycemic control in adults with type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, single-dose administration, both sexes, age 18-60.</p><h4>References</h4><ol><li><p>Hatorp, V (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. <i>Clinical pharmacokinetics</i> 41(7) 471–483. DOI:<a href=\"https://doi.org/10.2165/00003088-200241070-00002\">10.2165/00003088-200241070-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12083976/\">https://pubmed.ncbi.nlm.nih.gov/12083976</a></p></li><li><p>Ruzilawati, AB, &amp; Gan, SH (2010). CYP3A4 genetic polymorphism influences repaglinide&#x27;s pharmacokinetics. <i>Pharmacology</i> 85(6) 357–364. DOI:<a href=\"https://doi.org/10.1159/000302731\">10.1159/000302731</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20523106/\">https://pubmed.ncbi.nlm.nih.gov/20523106</a></p></li><li><p>Wu, L, et al., &amp; Ling, G (2020). Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation, characterization, pharmacokinetics, and . <i>Drug delivery</i> 27(1) 400–409. DOI:<a href=\"https://doi.org/10.1080/10717544.2019.1689313\">10.1080/10717544.2019.1689313</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31729898/\">https://pubmed.ncbi.nlm.nih.gov/31729898</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BX02;
